Coronary CT angiography–guided calcium modification during PCI for calcified coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

OPTIMAL is a prospective, multicenter, randomized trial enrolling 700 patients with flow-limiting stenosis (FFRCT ≤ 0.80) and moderate-to-severe coronary calcification on CCTA, randomized 1:1 to CCTA-guided versus IVUS-guided calcium modification before PCI. The CCTA-guided arm uses advanced CT-based calcium characterization to inform pre-procedural planning and choice of plaque-modification techniques, while the comparator arm follows contemporary intravascular ultrasound criteria for plaque preparation and stent optimization. The trial has two co-primary endpoints: superiority for final minimal stent area measured by IVUS and non-inferiority for 12-month target vessel failure (cardiac death, target-vessel MI, or ischemia-driven revascularization). The goal is to determine whether a noninvasive CT-based planning approach can improve procedural efficiency and stent expansion without worsening clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The subject must be at least 18 years of age and younger than 85 years old
* Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression\>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score\>140.
* All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm
* Subject must provide written informed consent before any study-related procedure

Exclusion Criteria:

* STEMI as the clinical presentation.
* Uncontrolled or recurrent ventricular tachycardia.
* Hemodynamic instability.
* Hemodialysis or peritoneal dialysis.
* Left main coronary artery stenosis \> 50%
* Atrial fibrillation, flutter, or arrhythmias during CT acquisition.
* Previous PCI in the target vessel or CABG.
* BMI ≥ 40 kg/m2
* Insufficient CT quality assessed by the Core lab.
* Comorbidity with life expectancy ≤ 2 years.
* Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
* The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
* The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
* The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
* Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3.
* The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
* The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy \<2 years for any non-cardiac cause.
* Subject is currently participating in another investigational drug or device clinical study.
* Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
* Unable to provide written informed consent (IC).

Where it's running

• Minneapolis Heart Institute
  Minneapolis, Minnesota, United States Recruiting
• NewYork-Presbyterian/Weill Cornell Medical Center
  New York, New York, United States Recruiting
• Azorg Hospital, Aalst
  Aalst, Belgium Recruiting
• Hospital Universitari Vall Hebron
  Barcelona, Spain Recruiting
• Hospital Universitario de Leon
  León, Spain Recruiting
• Hospital Universitario La Paz
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: Carolina Focella
• Email: cfocella@crf.org
• Phone: 001 917 753 6695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

• Comparing heart imaging techniques for coronary artery disease

  This study is testing if a new heart imaging method can better identify problems in patients suspected of having coronary artery disease compared to a traditional imaging technique.

  Recruiting Semmelweis University · Budapest, Budapest · NCT06670768

• Short-term high-dose rosuvastatin effects on coronary plaque using photon-counting CT

  This trial tests whether a short course of intensified rosuvastatin (40 mg) changes coronary plaque composition and flow on photon‑counting coronary CT in statin‑naive adults with stable chest pain and mild atherosclerosis.

  Recruiting Semmelweis University · Budapest, Budapest · NCT06603363

• Using a smartphone device to record 12-lead ECGs for heart attack diagnosis

  This study is testing a smartphone device that records heart activity to see if it can help doctors quickly diagnose heart attacks in adults who come to the emergency room with chest pain.

  Recruiting at 2 sites AliveCor · Rochester, Minnesota and 3 other locations · NCT06271577

• Evaluating the effectiveness and safety of Synergy XD and Megatron stents

  This study is testing how well and safely the Synergy XD and Megatron stents work for people with coronary artery disease compared to other stents in real-life situations.

  Recruiting at 19 sites Asan Medical Center · Anyang and 22 other locations · NCT05044273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.